These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 24471416)

  • 1. The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E; Galán AM
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):445-58. PubMed ID: 24471416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
    Kubli KA; Snead JA; Cheng-Lai A
    Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.
    Switzer MP; Wani P; Gosavi S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(2):98-104. PubMed ID: 26695421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M; Middeldorp S; Coppens M
    Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.
    Partida RA; Giugliano RP
    Future Cardiol; 2011 Jul; 7(4):459-70. PubMed ID: 21797743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper].
    Weiss TW; Rohla M; Dieplinger B; Domanovits H; Fries D; Vosko MR; Gary T; Ay C
    Wien Med Wochenschr; 2018 Apr; 168(5-6):133-143. PubMed ID: 28236004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Hurst KV; O'Callaghan JM; Handa A
    Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
    Barrios V; Escobar C
    Expert Rev Cardiovasc Ther; 2015; 13(7):811-24. PubMed ID: 26068539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishing Edoxaban's Role in Anticoagulation.
    Guirguis E; Brown D; Grace Y; Patel D; Henningfield S
    J Pharm Pract; 2016 Jun; 29(3):228-38. PubMed ID: 27169733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R; Kwong WJ; White RH; Goldhaber SZ
    Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edoxaban: Review of pharmacology and key phase I to III clinical trials.
    Plitt A; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):409-16. PubMed ID: 24607764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT
    Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.
    Chan NC; Bhagirath V; Eikelboom JW
    Vasc Health Risk Manag; 2015; 11():343-51. PubMed ID: 26170684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
    Morishima Y; Kamisato C; Honda Y
    Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
    Salazar DE; Mendell J; Kastrissios H; Green M; Carrothers TJ; Song S; Patel I; Bocanegra TS; Antman EM; Giugliano RP; Kunitada S; Dornseif B; Shi M; Tachibana M; Zhou S; Rohatagi S
    Thromb Haemost; 2012 May; 107(5):925-36. PubMed ID: 22398655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
    Gibson CM; Finks SW
    Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betrixaban - the next direct factor Xa inhibitor?
    Thoenes M; Minguet J; Bramlage K; Bramlage P; Ferrero C
    Expert Rev Hematol; 2016 Dec; 9(12):1111-1117. PubMed ID: 27809616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.